Financial News
All
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Macro
All Sentiment
Bullish
Neutral
Bearish
2,073 articles
Cancer Drug Developer Nanobiotix Denies Any Active Takeover Process
Nanobiotix S.A. (NASDAQ:NBTX) shares are up on Wednesday as the company responds to recent media speculation regarding potential acquisition...
Cancer Drug Developer Nanobiotix Denies Any Active Takeover Process
Nanobiotix S.A. (NASDAQ:NBTX) shares are up on Wednesday as the company responds to recent media speculation regarding potential acquisition...
📰
$100 Invested In argenx 5 Years Ago Would Be Worth This Much Today
argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 9.82% on an annualized basis producing an average annual return of 20.55%....
📰
Looking for a Growth Stock? 3 Reasons Why Star Equity Holdings (STRR) is a Solid Choice
Star Equity Holdings (STRR) is well positioned to outperform the market, as it exhibits above-average growth in financials.
📰
ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data
Novo Nordisk reports phase II data for UBT251, showing strong HbA1c reduction and weight loss. It plans for global studies and China phase III trials.
📰
NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data
Novo Nordisk reports phase II data for UBT251, showing strong HbA1c reduction and weight loss. It plans for global studies and China phase III trials.
NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data
Novo Nordisk reports phase II data for UBT251, showing strong HbA1c reduction and weight loss. It plans for global studies and China phase III trials.
NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data
Novo Nordisk reports phase II data for UBT251, showing strong HbA1c reduction and weight loss. It plans for global studies and China phase III trials.
NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data
Novo Nordisk reports phase II data for UBT251, showing strong HbA1c reduction and weight loss. It plans for global studies and China phase III trials.
What's Behind The Jump In Corcept Therapeutics Stock?
Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) are soaring Wednesday after the FDA approved a treatment for adults with platinum-resistant...
BTSG Growth Drivers in 2026 Across Specialty and Providers
BTSG leans on specialty and provider growth in 2026, with margin expansion expected to outpace revenue despite near-term pharmacy headwinds.
BTSG Growth Drivers in 2026 Across Specialty and Providers
BTSG leans on specialty and provider growth in 2026, with margin expansion expected to outpace revenue despite near-term pharmacy headwinds.
Will the Recent Label Expansion of BMY's Opdivo Boost Its IO Franchise?
Bristol Myers Squibb's Opdivo expansions highlight pharma companies' push to grow oncology franchises amid rising competition and pipeline innovation.
Will the Recent Label Expansion of BMY's Opdivo Boost Its IO Franchise?
Bristol Myers Squibb's Opdivo expansions highlight pharma companies' push to grow oncology franchises amid rising competition and pipeline innovation.
BTSG Growth Drivers in 2026 Across Specialty and Providers
BTSG leans on specialty and provider growth in 2026, with margin expansion expected to outpace revenue despite near-term pharmacy headwinds.
Will the Recent Label Expansion of BMY's Opdivo Boost Its IO Franchise?
Bristol Myers Squibb's Opdivo expansions highlight pharma companies' push to grow oncology franchises amid rising competition and pipeline innovation.
📰
Here's How Much $100 Invested In AbbVie 10 Years Ago Would Be Worth Today
AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.51% on an annualized basis producing an average annual return of 13.85%....
📰
Coherus Oncology (CHRS) Upgraded to Buy: Here's What You Should Know
Coherus Oncology (CHRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might...
REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?
Regeneron's rally reflects biotech momentum as pipeline wins and Dupixent growth offset Eylea erosion amid intensifying competition.
REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?
Regeneron's rally reflects biotech momentum as pipeline wins and Dupixent growth offset Eylea erosion amid intensifying competition.
REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?
Regeneron's rally reflects biotech momentum as pipeline wins and Dupixent growth offset Eylea erosion amid intensifying competition.
REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?
Regeneron's rally reflects biotech momentum as pipeline wins and Dupixent growth offset Eylea erosion amid intensifying competition.
Reasons Behind Holding Humana Shares: What Investors Need to Know
HUM's value-based care model, Medicare Advantage growth and CenterWell expansion drive momentum despite cost pressures and a 36% stock decline.
Reasons Behind Holding Humana Shares: What Investors Need to Know
HUM's value-based care model, Medicare Advantage growth and CenterWell expansion drive momentum despite cost pressures and a 36% stock decline.
Reasons Behind Holding Humana Shares: What Investors Need to Know
HUM's value-based care model, Medicare Advantage growth and CenterWell expansion drive momentum despite cost pressures and a 36% stock decline.
Reasons Behind Holding Humana Shares: What Investors Need to Know
HUM's value-based care model, Medicare Advantage growth and CenterWell expansion drive momentum despite cost pressures and a 36% stock decline.
📰
Myriad (MYGN) Up 4.1% Since Last Earnings Report: Can It Continue?
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
📰
Myriad (MYGN) Up 4.1% Since Last Earnings Report: Can It Continue?
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
📰
Why Is Hims & Hers Health (HIMS) Up 38% Since Last Earnings Report?
Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
📰
Why Is Hims & Hers Health (HIMS) Up 38% Since Last Earnings Report?
Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
LivaNova Expands OSA Care With FDA-Approved aura6000 System
LIVN wins FDA nod for its aura6000 sleep apnea system, marking a pivotal step in neurostimulation with strong trial results and new growth potential.
LivaNova Expands OSA Care With FDA-Approved aura6000 System
LIVN wins FDA nod for its aura6000 sleep apnea system, marking a pivotal step in neurostimulation with strong trial results and new growth potential.
LivaNova Expands OSA Care With FDA-Approved aura6000 System
LIVN wins FDA nod for its aura6000 sleep apnea system, marking a pivotal step in neurostimulation with strong trial results and new growth potential.
LivaNova Expands OSA Care With FDA-Approved aura6000 System
LIVN wins FDA nod for its aura6000 sleep apnea system, marking a pivotal step in neurostimulation with strong trial results and new growth potential.
Why Is Sarepta Therapeutics Stock Exploding Today?
Sarepta Therapeutics Inc. (NASDAQ:SRPT) shares are up on Wednesday following the announcement of promising clinical results from its siRNA programs...
📰
GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD
Phase 2b results for GH001 in TRD now published and peer-reviewed in JAMA Psychiatry
New peer-reviewed article in forthcoming issue of...